These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 33910078

  • 1. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
    Hofny HA, Mohamed MFA, Gomaa HAM, Abdel-Aziz SA, Youssif BGM, El-Koussi NA, Aboraia AS.
    Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
    [Abstract] [Full Text] [Related]

  • 2. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
    Ibrahim TS, Almalki AJ, Moustafa AH, Allam RM, Abuo-Rahma GEA, El Subbagh HI, Mohamed MFA.
    Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
    [Abstract] [Full Text] [Related]

  • 3. Molecular docking, discovery, synthesis, and pharmacological properties of new 6-substituted-2-(3-phenoxyphenyl)-4-phenyl quinoline derivatives; an approach to developing potent DNA gyrase inhibitors/antibacterial agents.
    Alagumuthu M, Arumugam S.
    Bioorg Med Chem; 2017 Feb 15; 25(4):1448-1455. PubMed ID: 28094220
    [Abstract] [Full Text] [Related]

  • 4. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
    Frejat FOA, Cao Y, Wang L, Zhai H, Abdelazeem AH, Gomaa HAM, Youssif BGM, Wu C.
    Arch Pharm (Weinheim); 2022 Jul 15; 355(7):e2100516. PubMed ID: 35363388
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
    Durcik M, Tammela P, Barančoková M, Tomašič T, Ilaš J, Kikelj D, Zidar N.
    ChemMedChem; 2018 Jan 22; 13(2):186-198. PubMed ID: 29206345
    [Abstract] [Full Text] [Related]

  • 6. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R, Zook C.
    Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3353-3358. PubMed ID: 28610977
    [Abstract] [Full Text] [Related]

  • 7. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
    Metwally NH, Abdallah SO, Mohsen MMA.
    Bioorg Chem; 2020 Apr 01; 97():103672. PubMed ID: 32145481
    [Abstract] [Full Text] [Related]

  • 8. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
    Werner MM, Patel BA, Talele TT, Ashby CR, Li Z, Zauhar RJ.
    Bioorg Med Chem; 2015 Sep 15; 23(18):6125-37. PubMed ID: 26320664
    [Abstract] [Full Text] [Related]

  • 9. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
    Jakopin Ž, Ilaš J, Barančoková M, Brvar M, Tammela P, Sollner Dolenc M, Tomašič T, Kikelj D.
    Eur J Med Chem; 2017 Apr 21; 130():171-184. PubMed ID: 28246042
    [Abstract] [Full Text] [Related]

  • 10. Design, Synthesis, and Evaluation of Novel Tyrosine-Based DNA Gyrase B Inhibitors.
    Cotman AE, Trampuž M, Brvar M, Kikelj D, Ilaš J, Peterlin-Mašič L, Montalvão S, Tammela P, Frlan R.
    Arch Pharm (Weinheim); 2017 Aug 21; 350(8):. PubMed ID: 28621824
    [Abstract] [Full Text] [Related]

  • 11. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
    Durcik M, Lovison D, Skok Ž, Durante Cruz C, Tammela P, Tomašič T, Benedetto Tiz D, Draskovits G, Nyerges Á, Pál C, Ilaš J, Peterlin Mašič L, Kikelj D, Zidar N.
    Eur J Med Chem; 2018 Jun 25; 154():117-132. PubMed ID: 29778894
    [Abstract] [Full Text] [Related]

  • 12. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
    Gjorgjieva M, Tomašič T, Barančokova M, Katsamakas S, Ilaš J, Tammela P, Peterlin Mašič L, Kikelj D.
    J Med Chem; 2016 Oct 13; 59(19):8941-8954. PubMed ID: 27541007
    [Abstract] [Full Text] [Related]

  • 13. Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study.
    Ammar YA, Micky JA, Aboul-Magd DS, Abd El-Hafez SMA, Hessein SA, Ali AM, Ragab A.
    Chem Biol Drug Des; 2023 Feb 13; 101(2):245-270. PubMed ID: 36305722
    [Abstract] [Full Text] [Related]

  • 14. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives.
    El-Shershaby MH, El-Gamal KM, Bayoumi AH, El-Adl K, Ahmed HEA, Abulkhair HS.
    Arch Pharm (Weinheim); 2021 Feb 13; 354(2):e2000277. PubMed ID: 33078877
    [Abstract] [Full Text] [Related]

  • 15. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ, Brickner SJ, Hamel JC, Brennan L, Casavant JM, Chen M, Chen T, Ding X, Driscoll J, Hardink J, Hoang T, Hua E, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Plotkin M, Reilly U, Robinson S, Schafer J, Shepard RM, Smith JF, Stone GG, Subramanyam C, Yoon K, Yuan W, Zaniewski RP, Zook C.
    Bioorg Med Chem Lett; 2013 May 15; 23(10):2955-61. PubMed ID: 23566517
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, characterization, theoretical, anti-bacterial and molecular docking studies of quinoline based chalcones as a DNA gyrase inhibitor.
    Abdullah MI, Mahmood A, Madni M, Masood S, Kashif M.
    Bioorg Chem; 2014 Jun 15; 54():31-7. PubMed ID: 24747187
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
    Alt S, Mitchenall LA, Maxwell A, Heide L.
    J Antimicrob Chemother; 2011 Sep 15; 66(9):2061-9. PubMed ID: 21693461
    [Abstract] [Full Text] [Related]

  • 18. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
    Ibrahim NM, Fahim SH, Hassan M, Farag AE, Georgey HH.
    Eur J Med Chem; 2022 Jan 15; 228():114021. PubMed ID: 34871841
    [Abstract] [Full Text] [Related]

  • 19. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
    Aziz HA, El-Saghier AMM, Badr M, Abuo-Rahma GEA, Shoman ME.
    Mol Divers; 2022 Jun 15; 26(3):1743-1759. PubMed ID: 34455532
    [Abstract] [Full Text] [Related]

  • 20. New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
    Durcik M, Nyerges Á, Skok Ž, Skledar DG, Trontelj J, Zidar N, Ilaš J, Zega A, Cruz CD, Tammela P, Welin M, Kimbung YR, Focht D, Benek O, Révész T, Draskovits G, Szili PÉ, Daruka L, Pál C, Kikelj D, Mašič LP, Tomašič T.
    Eur J Med Chem; 2021 Mar 05; 213():113200. PubMed ID: 33524686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.